Acrux (ASX:ACR) has signed a 10-year agreement with Servacure Trading to market and distribute its food and drug administration-approved Dapsone 5% Gel in Saudi Arabia, according to a Thursday filing with the Australian bourse.
The product, launched in the US in April 2024 for treating acne vulgaris and available in 60g and 90g packs, will have its regulatory approval and manufacturing managed by Servacure under the agreement, the filing said.
The company will earn a fixed fee per unit shipped monthly, with options to renew the contract after the initial term, the filing added.